JP2019509976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509976A5 JP2019509976A5 JP2018528648A JP2018528648A JP2019509976A5 JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5 JP 2018528648 A JP2018528648 A JP 2018528648A JP 2018528648 A JP2018528648 A JP 2018528648A JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021163120A JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262303P | 2015-12-02 | 2015-12-02 | |
| US62/262,303 | 2015-12-02 | ||
| PCT/US2016/064394 WO2017096026A1 (en) | 2015-12-02 | 2016-12-01 | Antibodies specific to glycosylated pd-1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Division JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509976A JP2019509976A (ja) | 2019-04-11 |
| JP2019509976A5 true JP2019509976A5 (enExample) | 2020-01-16 |
| JP7003036B2 JP7003036B2 (ja) | 2022-02-04 |
Family
ID=58797717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528648A Active JP7003036B2 (ja) | 2015-12-02 | 2016-12-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10858432B2 (enExample) |
| EP (1) | EP3383412A4 (enExample) |
| JP (2) | JP7003036B2 (enExample) |
| KR (1) | KR102809728B1 (enExample) |
| CN (1) | CN109152798B (enExample) |
| WO (1) | WO2017096026A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| DK3356411T3 (da) | 2015-10-02 | 2021-09-06 | Hoffmann La Roche | Bispecifikke antistoffer, der er specifikke for PD1 og TIM3 |
| CN109152798B (zh) * | 2015-12-02 | 2022-10-21 | 斯特库比股份有限公司 | 特异于糖基化的pd-1的抗体及其使用方法 |
| KR20180130541A (ko) * | 2016-03-29 | 2018-12-07 | 주식회사 에스티큐브앤컴퍼니 | 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법 |
| KR20190031299A (ko) | 2016-07-20 | 2019-03-25 | 주식회사 에스티큐브 | 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법 |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| EP3568157A4 (en) * | 2017-01-13 | 2021-01-06 | National Research Council of Canada | PROCESS FOR THE OPTIMIZATION OF PEPTIDIC IMMUNO-EPITOPE BY GLYCOSYLATION, ASSOCIATED OPTIMIZED PEPTIDE AND ITS USE FOR CONJUGATE VACCINES |
| EP4201953A1 (en) | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
| WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
| EP3635007A1 (en) | 2017-06-06 | 2020-04-15 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
| TWI708787B (zh) | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及其用途 |
| EP3773916A4 (en) * | 2018-04-04 | 2021-12-15 | TrueBinding, Inc. | PROCEDURES AND COMPOSITIONS FOR BLOCKING THE INTERACTION BETWEEN NON-GLYCOSYLATED PD-1 POLYPEPTIDES |
| AU2019288276B2 (en) | 2018-06-20 | 2026-02-12 | Incyte Corporation | Anti-PD-1 antibodies and uses thereof |
| CN111166867B (zh) * | 2018-11-09 | 2022-12-20 | 中国科学院分子细胞科学卓越创新中心 | Pd-1泛素化激动剂的功能与用途 |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| KR20220030956A (ko) | 2019-07-05 | 2022-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료 |
| TW202120550A (zh) | 2019-08-08 | 2021-06-01 | 日商小野藥品工業股份有限公司 | 雙特異性蛋白質 |
| CN114729045B (zh) * | 2019-09-26 | 2025-09-09 | 斯特库比公司 | 对糖基化的ctla-4特异性的抗体及其使用方法 |
| CN114829404B (zh) | 2019-10-09 | 2025-09-09 | 斯特库比公司 | 对糖基化的lag3特异的抗体及其使用方法 |
| CN114316022A (zh) * | 2020-09-30 | 2022-04-12 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| KR20240005794A (ko) * | 2021-05-18 | 2024-01-12 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항 pd-1 폴리펩티드 및 그의 용도 |
| CN113372447A (zh) * | 2021-05-26 | 2021-09-10 | 重庆中元汇吉生物技术有限公司 | 抗pivka-ii单克隆抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| WO2004056875A1 (en) * | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| CA2572098C (en) | 2004-06-30 | 2015-01-27 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| KR101586617B1 (ko) * | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| WO2009089149A1 (en) | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| JP2012500652A (ja) * | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| PL2342226T3 (pl) * | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| WO2011109246A1 (en) | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
| US9556281B2 (en) | 2011-08-15 | 2017-01-31 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
| EP2755688A4 (en) | 2011-10-27 | 2014-08-06 | Nkt Therapeutics Inc | HUMANIZED ANTIBODIES AGAINST INKT |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| CN104411720B (zh) * | 2012-07-02 | 2018-05-11 | 协和发酵麒麟株式会社 | 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| LT3702373T (lt) * | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| AU2014339900B2 (en) | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| HUE046249T2 (hu) * | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| SG10202002334PA (en) | 2013-12-17 | 2020-05-28 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN103897036B (zh) * | 2014-03-24 | 2016-02-24 | 郑州大学 | 一种pd-1蛋白胞外段亲和肽l8及其应用 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN114380909A (zh) | 2015-03-30 | 2022-04-22 | 斯特库比股份有限公司 | 特异性针对糖基化的pd-l1的抗体及其使用方法 |
| WO2017017874A1 (en) | 2015-07-29 | 2017-02-02 | Sharp Kabushiki Kaisha | Method for device-to-device relay procedure |
| DK3356411T3 (da) * | 2015-10-02 | 2021-09-06 | Hoffmann La Roche | Bispecifikke antistoffer, der er specifikke for PD1 og TIM3 |
| AU2016329251B2 (en) * | 2015-10-02 | 2023-02-02 | F. Hoffmann-La Roche Ag | Anti-PD1 antibodies and methods of use |
| CN109152798B (zh) | 2015-12-02 | 2022-10-21 | 斯特库比股份有限公司 | 特异于糖基化的pd-1的抗体及其使用方法 |
-
2016
- 2016-12-01 CN CN201680078477.9A patent/CN109152798B/zh active Active
- 2016-12-01 KR KR1020187018671A patent/KR102809728B1/ko active Active
- 2016-12-01 JP JP2018528648A patent/JP7003036B2/ja active Active
- 2016-12-01 EP EP16871487.1A patent/EP3383412A4/en active Pending
- 2016-12-01 WO PCT/US2016/064394 patent/WO2017096026A1/en not_active Ceased
- 2016-12-01 US US15/778,663 patent/US10858432B2/en active Active
-
2020
- 2020-11-13 US US17/097,892 patent/US11981736B2/en active Active
-
2021
- 2021-10-01 JP JP2021163120A patent/JP7455787B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060423B2 (en) | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies | |
| US11891444B2 (en) | Variable regions for NKp46 binding proteins | |
| US10081680B2 (en) | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies | |
| JP2019502405A5 (enExample) | ||
| CA3043691C (en) | Antibody binding specifically to cd66c and use thereof | |
| JP2021512604A5 (enExample) | ||
| KR20250169224A (ko) | 암의 치료를 위한 항체, 또는 그의 항원-결합 단편의 조합물 및 그의 조성물 | |
| JP2019512210A5 (enExample) | ||
| JP7811028B2 (ja) | ヒトｃｘｃｌ１６抗体およびその使用 | |
| CN120958025A (zh) | 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途 | |
| JP2022552282A5 (enExample) | ||
| TW202336033A (zh) | 抗體之新穎組合及用途 | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела | |
| HK40040747A (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| HK1262017A1 (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| EA049228B1 (ru) | Набор для диагностики или иммунотерапии заболевания, ассоциированного с cd47 |